CMP 001

Drug Profile

CMP 001

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; QbG10; Virus-like particle-based cancer vaccine - Checkmate; VLP-based cancer vaccine - Checkmate

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Checkmate Pharmaceuticals; Cytos Biotechnology
  • Class Allergy immunotherapies; Antiallergics; Cancer vaccines; Oligonucleotides; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Non-small cell lung cancer
  • Preclinical Lymphoma
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 27 Apr 2018 Sheba Medical Center, in collaboration with Checkmate Pharmaceuticals and Bristol-Myers Squibb, plans a phase I trial for Colorectal cancer, Liver metastases (Combination therapy, Second-line therapy or greater, Recurrent, Metastatic disease, Inoperable/Unresectable) in Israel (Intratumoural) in July 2018 (NCT03507699)
  • 17 Apr 2018 Safety and efficacy data from a phase Ib trial in Malignant melanoma presented at the Annual Meeting of American Association for Cancer Research (AACR-2018)
  • 15 Mar 2018 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT03438318; 9238627)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top